SUNDAY, MARCH 19
Arrival and Registration

MONDAY, MARCH 20
Welcome and Keynote Address (X3)
Dean Sheppard, University of California, San Francisco, USA
Fibrosis Across Organs: From Mechanisms to Therapies

Welcome and Keynote Address (X4)
Samuel Klein, Washington University School of Medicine, USA
Extrahepatic Lipid Processing and NAFLD/NASH

Fibrosis Initiation Concepts: Viral Infection, Trauma, Telomere Dysfunction (X3)
Gisli Jenkins, Imperial College London, UK
Pulmonary Fibrosis in Patients with Severe COVID-19 Disease
Christine Kim Garcia, Columbia University Medical Center, USA
Telomere Dysfunction in Pulmonary Fibrosis after COVID19 Infection
Rafael Kramann, RWTH Aachen University, Germany
Drivers of Cardiac and Kidney Fibrosis

Short Talks Chosen from Abstracts

Metabolic Syndrome and Diabetes as Drivers of NAFLD/NASH (X4)
Filip K. Knop, Gentofte Hospital, University of Copenhagen, Denmark
Hepatic Glucagon Action in NAFLD
Leigh A. Goedeke, Icahn School of Medicine at Mount Sinai, USA
NAFLD/NASH and Insulin Resistance: Lessons Learned from Liver-Directed Mitochondrial Uncouplers
Matthew Watt, University of Melbourne, Australia
Peripheral Insulin Resistance and Mediators of NAFLD/NASH

Short Talks Chosen from Abstracts

Workshop 1: New Horizons: Emerging Preclinical Models to Study Tissue Injury, Fibrosis and Regeneration (Joint)

Poster Session 1

TUESDAY, MARCH 21
Fibrosis Initiation Concepts: Aging, Oncogenic Injury, Autoimmunity (X3)
Pura Muñoz Cánoves, University Pompeu Fabra, Spain
Muscle Fibrosis and Regenerative Decline with Aging
Jörg H.W. Distler, University of Erlangen-Nuremberg, Germany
Drivers of Fibrosis in Systemic Autoimmune Rheumatic Diseases
Ellen Puré, University of Pennsylvania, USA
CAFs and their Influence on Tumor Progression and Immunity
Kang Liu, Boehringer Ingelheim Pharmaceuticals, Inc., USA
Targeting the Tumor Stroma to Cure Cancers

Short Talks Chosen from Abstracts

Hepatic Lipid Management and Steatosis (X4)
Elizabeth J. Parks, University of Missouri, USA
De novo Lipogenesis and Hepatic Lipid Flux in NAFLD
Brent A. Neuschwander-Tetri, St. Louis University, USA
Lipotoxicity and NAFLD/NASH
James A. Olzmann, University of California, Berkeley, USA
Mechanisms of Cellular Lipid Storage and Lipotoxicity

Short Talks Chosen from Abstracts

Workshop 2: Fibrosis Research Funding and Partnering Academia/Pharma (X3)

Short Talks Chosen from Abstracts

Fibrosis Drivers: Cellular Crosstalks (X3)
Valerie Horsley, Yale University, USA
Macrophage – Fibroblast Crosstalk in Tissue Repair, Regeneration and Fibrosis
Shahin Rafii, Weill Cornell Medical College, USA
Liver Sinusoidal Endothelium Dysfunction in Hepatic Fibrosis and Regeneration
Boris Hinz, University of Toronto, Canada
Fibroblast-Macrophage Mechanobiology in Tissue Repair and Fibrosis

Short Talks Chosen from Abstracts

Pathways and Progression of NAFLD/NASH (X4)
Olivier Govaere, Newcastle University, UK
Hepatic Pathways Regulating NAFLD/NASH: Insights from Transcriptomic Approaches
Neil C. Henderson, University of Edinburgh, Queen’s Medical Research Institute, UK
Insights into NASH and Liver Fibrosis from Single Cell Analyses

* Session Chair † Invited but not yet accepted  Program current as of November 17, 2022. Meal formats are based on meeting venue.
For the most up-to-date details, visit https://www.keystonesymposia.org.
Jacquelyn Maher, University of California, San Francisco, USA
Advances in Understanding and Leveraging Regulatory Pathways in NAFLD/NASH
Short Talks Chosen from Abstracts

Fibrosis Amplification Loops: Mechanobiology, Epigenetics, Senescence (X3)

Ana L. Mora, Ohio State University, USA
Cellular Senescence in Lung Fibrosis

Nan Tang, National Institute of Biological Sciences, China
Mechanobiology of Stem Cells in Tissue Regeneration and Fibrosis

Jelena Mann, Newcastle University, UK
Epigenetic Mechanisms in Liver Fibrosis and Cancer

Scott M. Turner, Plant Therapeutics, USA
Application of Molecular Imaging and Target Engagement Studies in the Development of PLN-74809

Short Talks Chosen from Abstracts

Cellular Processes and Hepatic Dysfunction (X4)

Michael Roden, Universitätsklinikum Düsseldorf, Germany
Alterations of Mitochondrial Function in NAFLD

Guadalupe Sabio Buzo, Spanish National Centre for Cardiovascular Research, Spain
Stress Activated Kinases and NAFLD/NASH

Utpal B. Pajvani, Columbia University Medical Center, USA
Activation of Morphogenic Pathways in NASH

Beatrice Baily-Maître, INSERM, France
Endoplasmic Creticulum Stress and NAFLD/NASH

Short Talks Chosen from Abstracts

Fibrosis Resolution: Repair and Regeneration (X3)

David Lagares, Massachusetts General Hospital/Harvard Medical School, USA
Cell-Specific Senolytics to Reverse Established Lung Fibrosis

Edward E. Morrisey, University of Pennsylvania, USA
Lung Regeneration: Underlying Molecular Mechanisms and Emerging Concepts

Clemens A. Schmitt, Max Delbrück Center for Molecular Medicine, Germany
Virus-induced Senescence is a Driver and Therapeutic Target in COVID-19

Short Talks Chosen from Abstracts

Emerging Biology and Function of Genetic Links to NAFLD/NASH (X4)

Paola Dongiovanni, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Italy
Compound Genetic Mutations and NASH

Yaron Rotman, NIDDK, National Institutes of Health, USA
Insights into HSD17beta13 Biology

Daniel Lindén, AstraZeneca, Sweden
Advances in PNPLA3 Function in NASH

Short Talks Chosen from Abstracts
Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies (X3)
Scientific Organizers: David Lagares, Boris Hinz and Carine Boustany
Supported by the Directors' Fund

Metabolic and Molecular Mechanisms of NAFLD/NASH (X4)
Scientific Organizers: James Trevaskis, Jacquelyn Maher and Quentin M. Anstee
March 19-23, 2023 • Fairmont Banff Springs • Banff, AB, Canada
Supported by the Directors' Fund

Sven Francque, University Hospital Antwerp, Belgium
Overview of NASH Therapeutics

Kitty Yale, Akero Therapeutics, USA
FGF-21 Therapy in NASH and Fibrosis

Rhianna C. Laker, AstraZeneca, USA
GLP-1/Glucagon Dual Agonism and NASH

James Trevaskis, Eli Lilly, USA
Combination Approaches for the Treatment of NASH

Short Talks Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X3)
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X4)

FRIDAY, MARCH 24
Departure